For the Inventor, By the Inventor

Enter assignee name

Shanghai, China

Shanghai Hansoh Biomedical Co., Ltd.

USPTO Granted Patents = 14

EPO Patents = 6

Forward Citations = 3

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Rudi Bao (11 out of 12 patents)

Fujun Zhang (5 out of 5 patents)

Peng Gao (5 out of 31 patents)

4. Lei Liu (4 out of 46 patents)

5. Guangjun Sun (4 out of 4 patents)

6. Shaobao Wang (4 out of 5 patents)

7. Yidong Su (4 out of 9 patents)

8. Songliang Tan (3 out of 4 patents)

9. Wenhua Xiu (3 out of 3 patents)

10. Xiaopo Chen (3 out of 3 patents)

11. Mingsong Wei (2 out of 2 patents)

12. Jun Wang (2 out of 153 patents)

13. Song Li (1 out of 14 patents)

14. Hua Ying (1 out of 9 patents)

15. Weikang Tao (1 out of 49 patents)

14 patents: Sort by Forward Citations

1. 12497396 - Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers (2025-12-16),

2. 12497366 - Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof (2025-12-16),

3. 12466823 - Inhibitor containing bicyclic derivative, preparation method therefor and use thereof (2025-11-11),

4. 12459931 - Benzothiophene derivative regulator, preparation method therefor and use thereof (2025-11-04),

5. 12377163 - Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof (2025-08-05),

6. 12139508 - Steroid derivative regulators, method for preparing the same, and uses thereof (2024-11-12),

7. 11667631 - FGFR4 inhibitor, preparation method therefor, and applications thereof (2023-06-06),

8. 11661437 - Steroid derivative regulators, method for preparing the same, and uses thereof (2023-05-30),

9. 11608332 - FGFR4 inhibitor and preparation method and use thereof (2023-03-21),

10. 11472882 - Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof (2022-10-18),

11. 11155534 - EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application (2021-10-26),

12. 11136324 - Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors (2021-10-05),

13. 10428081 - EGFR inhibitor, preparation method and use thereof (2019-10-01),

14. 10259820 - EGFR inhibitor, preparation method and use thereof (2019-04-16),

Shanghai Hansoh Biomedical Co., Ltd. is a leading pharmaceutical company in China, specializing in researching, developing, manufacturing, and marketing innovative drugs. With a strong focus on oncology, psychiatry, and cardiovascular diseases, the company is committed to improving the health and quality of life of patients worldwide. Hansoh Biomedical is dedicated to advancing medical science and bringing cutting-edge treatments to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

14 Patents

#172 in Shanghai

#1,812 in China

#40,903 in the World

Shanghai, China

Shanghai Hansoh Biomedical Co., Ltd.

Forward Citations = 3

35 inventors:

Rudi Bao (11 out of 12 patents)

Fujun Zhang (5 out of 5 patents)

Peng Gao (5 out of 31 patents)

4. Lei Liu (4 out of 46 patents)

5. Guangjun Sun (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…